Informational Webinars on Newly Approved Treatment for Thalassemia

AQVESME (which many may previously have known as mitapivat) was recently approved by the FDA for use in the U.S. in both alpha and beta Thalassemia, and for both transfusion-dependent and non-transfusion-dependent Thalassemia.

CAF is holding a webinar on Wednesday, February 11, at 8:00 p.m. Eastern, during which Dr. Scott Peslak of the Hospital of the University of Pennsylvania will speak about AQVESME and answer questions.

The link for this webinar is:

All U.S. Thalassemia patients are invited to join us to get answers to questions you may have about this new treatment option.

In addition, Agios Pharmaceuticals is holding webinars this weekend on January 31 and February 1, during which doctors will answer questions about AQVESME. The information and QR codes for these webinars are below.